Full Title
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants with Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206)Purpose
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
Contact
For more information or to see if you can join this study, please call Dr. Vicky Makker’s office at 646-888-4224.
Protocol
26-018
Phase
Phase II (phase 2)
Investigator
Co-Investigators
ClinicalTrials.gov ID
NCT06695845